C12N 2760/12134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/12134 (Use of virus or viral component as vaccine) appears on 16 US grants and 23 published applications in this corpus.
Search patents in C12N- Granted patents
- 16
- Published applications
- 23
- Assignees
- 21
- Inventors
- 37
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 3 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 1 | 2 |
| 2018 | 1 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 2 |
| 2021 | 2 | 1 |
| 2022 | 0 | 3 |
| 2023 | 1 | 2 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines27 Jan 2026US 12,533,410 B2Arcturus Therapeutics, Inc.
- Systems and methods for the production of human polyclonal antibodies16 Dec 2025US 12,497,443 B2Sab, LLC
- Stabilized recombinant hantaviral spike proteins comprising mutations in Gc15 Aug 2023US 11,723,968 B2FundacióN Ciencia Para La Vida
- Sin Nombre virus full-length M segment-based DNA vaccines26 Oct 2021US 11,155,834 B2The Government of the United States, as represented by the Secretary of the Army
- Systems and methods for the production of human polyclonal antibodies27 Jul 2021US 11,072,649 B2Sab, LLC
- Systems and methods for the production of human polyclonal antibodies11 Jun 2026US 2026/0159574 A1Sab, LLC
- mRNA Vaccines Against Hantavirus24 Apr 2025US 2025/0127870 A1Board of Regents, The University of Texas System
- Immunogenic formulation containing a modified bcg strain expressing an andesvirus protein (andv) useful for preventing and treating hanta-andv virus infections7 Dec 2023US 2023/0390378 A1Pontificia Universidad Catolica De Chile
- Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid Vaccines7 Dec 2023US 2023/0390389 A1Arcturus Therapeutics, Inc.
- Hantavirus antigenic composition1 Sep 2022US 2022/0275346 A1Secretary of State for Health and Social Care
Most cited
By later US patents
- Antigen library immunization76US 6,541,011 B2Maxygen, Inc. · 2003
- Flavivirus and alphavirus recombinant antigen libraries13US 6,569,435 B1Maxygen, Inc. · 2003
- Polynucleotides encoding flavivirus and alphavirus multivalent antigenic polypeptides11US 6,576,757 B1Maxygen, Inc. · 2003
- Puumala virus full-length M segment-based DNA vaccines5US 8,183,358 B2The United States of America as represented by the Secretary of the Army · 2012
- Systems and methods for the production of human polyclonal antibodies2US 11,072,649 B2Sab, LLC · 2021